Fulcrum Therapeutics (FULC) Revenue (2020 - 2024)

Fulcrum Therapeutics (FULC) has reported Revenue for 5 consecutive years, with $80.0 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Revenue rose 8990.91% year-over-year to $80.0 million; the TTM figure through Jun 2025 stood at $80.0 million (down 2.0% YoY), while the FY2024 annual figure was $80.0 million, up 2752.05% from the prior year.
• Revenue climbed to $80.0 million in Q2 2024 per FULC's latest filing, from $871000.0 in the prior quarter.
• Across five years, Revenue topped out at $80.0 million in Q2 2024 and bottomed at $295000.0 in Q1 2023.
• Historically, Revenue has averaged $6.9 million across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2023 — Revenue sank 88.62% — and 2024, when it soared 8990.91%.
• Fulcrum Therapeutics' Revenue stood at $4.2 million in 2020, then rose by 19.72% to $5.1 million in 2021, then plunged by 86.46% to $685000.0 in 2022, then increased by 27.15% to $871000.0 in 2023, then jumped by 9084.85% to $80.0 million in 2024.
• Business Quant data shows FULC's Revenue at $80.0 million in Q2 2024, $871000.0 in Q4 2023, and $759000.0 in Q3 2023.